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Abstract 
    Angiotensin II (Ang II) and platelet-derived growth factor-BB (PDGF-BB) are associated 
with excessive cell migration, proliferation and many growth-related diseases. However, 
whether these agents utilise similar mechanisms to trigger vascular pathologies remain to be 
explored. The effects of Ang II and PDGF-BB on coronary artery smooth muscle cell 
(CASMC) migration and proliferation were investigated via Dunn chemotaxis assay and the 
measurement of [
3
H]thymidine incorporation rates, respectively. Both atherogens produced 
similar degrees of cell migration which were dramatically inhibited by mevastatin (10 nM). 
However, the inhibitory effects of losartan (10 nM) and MnTBAP (a free radical scavenger; 
50M) were found to be unique to Ang II-mediated chemotaxis. In contrast, MnTBAP, 
apocynin (an antioxidant and phagocytic NADPH oxidase inhibitor; 500 µM), mevastatin and 
pravastatin (100 nM) equally suppressed both Ang II and PDGF-BB-induced cellular growth. 
Although atherogens produced similar changes in NADPH oxidase, NOS and superoxide 
dismutase activities, they differentially regulated antioxidant glutathione peroxidase activity 
which was diminished by Ang II and unaffected by PDGF-BB. Studies with signal 
transduction pathway inhibitors revealed the involvement of multiple pathways i.e. protein 
kinase C, tyrosine kinase and MAPK in Ang II- and/or PDGF-BB-induced aforementioned 
enzyme activity changes. In conclusion, Ang II and PDGF-BB may induce coronary 
atherosclerotic disease formation by stimulating CASMC migration and proliferation through 
agent-specific regulation of oxidative status and utilisation of different signal transduction 
pathways. 
Keywords: Atherosclerosis, Arteries, Superoxide anion, Nitric oxide, Antioxidants 
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1. Introduction 
    Coronary atherosclerosis, associated with enhanced oxidative stress, continues to be the 
leading cause of morbidity and mortality in the Western World. Atherosclerosis is a 
progressive inflammatory disease that ultimately leads to formation of advanced or 
complicated focal lesions which develop subsequent to a series of specific cellular and 
molecular responses including enhanced vascular smooth muscle cell (VSMC) proliferation 
and migration [1]. Several agents including platelet-derived growth factor (PDGF) exacerbate 
atherogenesis through inducing VSMC proliferation and plaque neovascularisation. The 
HMG-CoA reductase inhibitors (statins) e.g. simvastatin have been implicated in the 
suppression of PDGF-induced DNA synthesis in human glomerular mesangial cells in 
addition to reducing the risk of primary and secondary events [2-4]. Another non-lipid-
lowering effect of statins is their ability to prevent migration of VSMC to PDGF by blocking 
the production of isoprenoids which are required for prenylation of small GTP-binding 
proteins, such as Ras and Rho, involved in cell proliferation and migration control [5]. Hence, 
the suppression of PDGF-induced mitogenesis and migration should dramatically limit its 
atherogenic effects.  
    Similar to PDGF, angiotensin II (Ang II), the active component of the renin-angiotensin 
system, stimulates VSMC proliferation and migration and is therefore implicated in 
atherogenesis [6]. Previous data have concluded that Ang II type 1 receptor (AT1R) blockers 
(ARB) exert direct anti-atherosclerotic effects [7,8]. Ang II displays its proatherogenic effects 
through AT1R stimulation and consequent NADPH oxidase enzyme activation to generate 
excess levels of superoxide anion (O2
.-
), a reactive oxygen species (ROS) [9]. The effects of 
ROS range from eliciting vasoconstriction to scavenging nitric oxide (NO), an endogenous 
vasodilator produced from L-arginine by NO synthase (NOS) [10,11]. Under physiological 
conditions, O2
.-
 is converted to H2O2 by superoxide dismutases (SOD) which is then further 
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metabolised to H2O by catalase and glutathione peroxidase (GPx) [12]. However, in 
pathological conditions, O2
.-
 may lead to atherosclerotic plaque formation via diminished 
concentrations and/or aberrant regulations of antioxidant enzymes. 
    In addition to their respective roles in SMC proliferation, migration and oxidative stress, 
Ang II and PDGF share somewhat similar signal transduction characteristics such as 
activation of tyrosine kinases and mitogen-activated protein kinases (MAPK) [13,14]. 
Furthermore, recent data have implicated PDGF-BB in Ang II-induced chemotaxis and 
revealed the ability of Ang II to activate PDGF- receptor [15,16]. Taken these close 
functional interactions into account, the present study examined whether mechanistic 
dis/similarities exist between these atherogens to trigger vascular pathologies. To this end the 
putative differences in: i- oxidative status as assessed by pro- and anti-oxidant enzyme 
activities; ii- proliferative and migratory responses; iii- signal transduction pathways involved 
in atherogen-mediated oxidative stress regulation, and iv- the correlation of ARBs, an 
antioxidant, a free radical scavenger or statins to cell growth and enzyme activities were 
investigated using coronary artery smooth muscle cells (CASMC) exposed to physio-
pathological concentrations of Ang II or PDGF-BB.  
2. Materials and Methods  
2.1. Human CASMC culture and characterisation 
    Human CASMC (n=3 donors) were purchased from Cambrex (UK) and cultured in 
SmGM-2 according to manufacturer’s instructions. Cells grown on coverslips were rinsed 
with ice-cold PBS and fixed in 4% formaldehyde for 20 min at room temperature before 
permeabilisation with 0.1% Triton X-100. To characterise the cells as SMC they were stained 
with a monoclonal antibody raised against SM -actin for 1 h in the dark at 4oC prior to 
examination by confocal microscopy (Micro Radiance, Bio-Rad, UK). Moreover, the cells 
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were stained positive for SM myosin, calponin and caldesmin by the commercial company. 
CASMC between passages 4 and 8 were used in the current study. 
2.2. Manipulation of cell growth 
    To exclude potential effects produced by differences in cell density, an identical number of 
cells was seeded into flasks (0.5 x 10
6
). Cell passages were performed using a 1:3 ratio and 
culture medium was replaced every 24 h. This ensured that the number of mitoses was 
unaltered amongst experiments.  
2.3. [
3
H]Thymidine incorporation 
    [
3
H]Thymidine (37 kBq/ml) was directly added to the culture medium with the test 
compounds and incubated with CASMC for 18 h. Incubations were stopped by removing the 
medium, washing the cells with ice-cold 5% trichloroacetic acid (TCA) and incubating them 
in 5% TCA on ice for 20 min. After two additional washings with cold 95% ethanol, 
precipitates were solubilised with buffer (0.1 M NaOH, 2% Na2CO3, 1% sodium dodecyl 
sulphate) and their radioactivity was analysed by liquid scintillation counting. Data were 
expressed as counts per minute (cpm) [
3
H]thymidine incorporated per flask. 
2.4. Migration Assays 
    Cell migration was assessed by direct observation and recording of cell behaviour in 
concentrations of recombinant human PDGF-BB (5-50 ng/ml) or Ang II (5-50 nM) using the 
Dunn chemotaxis chamber (Weber Scientific International, Teddington, UK). This apparatus 
permits the direction of movement of individual cells to be measured in relation to the 
direction of the gradient, as well as the time course to be followed.  The apparatus was set up, 
filmed by time-lapse computer photography and data analysed as previously described 
[17,18]. The rationale behind all chemotaxis experiments was the same; the potential 
chemoattractant was placed in the outer well of the Dunn chamber in addition to the 
components that were available in the inner well to rule out the contribution of those other 
components. Between the 2 wells cells on an inverted coverslip are exposed to the 
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chemoattractant gradient and can be directly filmed for up to 24 h when the gradient will start 
to break down. For example, for Ang II experiments SmGM-2 was placed in the inner well 
and SmGM-2 with varying concentrations (5-50 nM) of Ang II in the outer well.  
    All cells were serum starved for 18 h prior to migration assays to exclude effects 
attributable to factors present in serum other than the expected chemoattractant. Experiments 
were run for 18 h with a time-lapse interval of 10 min. Minimum of 30 cells from three 
independent experiments were analysed for each study and the proportion of cells migrating 
towards the atherogenic agent are given as a percentage of total cells in that field.  
2.5. Measurement of NADPH oxidase activity and detection of O2
.-
 levels 
    O2
.-
 levels were measured by cytochrome C reduction assay. Briefly, CASMC were 
collected in Hanks’ balanced salt solution at a density of 20 x 106 cells/ml. Aliquots (250 µl) 
containing 50 µM cytochrome C were then incubated for 60 min at 37°C. O2
.-
 generation was 
measured as the superoxide dismutase (10 µg/ml)-inhibitable reduction of cytochrome C and 
monitored as the change in absorbance at 550 nm using a GENios plate reader (TECAN). 
Absorbances were recorded for 8 min with 60 sec intervals and the activity was calculated as 
pmoles O2
.-
 per mg protein following subtraction of background levels at 550 nm. 
    NADPH oxidase activity was measured in similar experiments via detection of changes in 
O2
.-
 levels by cytochrome C reduction assays. In order to ascribe all cytochrome C reduction 
to NADPH oxidase, the inhibitors of other ROS-generating enzymes i.e. L-NAME (100 M, 
NOS inhibitor), rotenone (50 M, mitochondrial complex I inhibitor), allopurinol (100 M, 
xanthine oxidase inhibitor) or indomethacin (50 M, cyclooxygenase inhibitor) were added 
simultaneously to aliquots at the beginning of 60 min incubation period prior to determining 
O2
-
 generation. 
    NADPH oxidase activity was also measured by lucigenin-enhanced chemiluminescent 
detection of O2
.-
. Briefly, cells were lysed on ice in lysis buffer containing 1 mM EGTA, 20 
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mM monobasic potassium phosphate (pH 7.0), 0.5 g/ml leupeptin, 10 g/ml aprotinin, 0.7 
g/ml pepstatin and 0.5 mM phenylmethylsulfonyl fluoride. The reaction buffer contained 1 
mM EGTA, 150 mM sucrose, 5  lucigenin and 1 mM NADPH. The reaction was initiated 
by addition of 50-200 g of protein in 100 l of homogenate and luminescence was recorded 
every 60 sec for 10 min using a luminometer following subtraction of the counts obtained 
from a buffer blank. 
2.6. Isolation of cellular membranes  
    Differential centrifugation was used to isolate subcellular fractions. CASMC were 
suspended (2 x 10
7
/ml) in MOPS-KOH buffer (20 mM MOPS-KOH, 250 mM sucrose, pH 
7.4) containing 1 mM PMSF, 0.1 mM EDTA, 2 M leupeptin and 2 M pepstatin. Cells were 
disrupted successively by snap freezing in liquid nitrogen, two cycles (15 sec each) of 
homogenisation and two cycles of sonication at 100 W for 20 sec on ice. The homogenate 
was quickly centrifuged at 800 x g for 10 min to remove nuclei and unbroken cells. The 
supernatant was centrifuged at 20,000 x g for 20 min at 4
o
C to obtain a pellet of 
submitochondrial particles and smaller organelles. The supernatant was centrifuged again at 
100,000 x g for 60 min to collect membrane fractions to be used in the experiments. The 
pellets were resuspended in MOPS-KOH buffer and the quantities of the proteins were 
determined using a kit (Pierce) prior to detection of NADPH oxidase activities.  
2.7. NOS Assay 
    NOS activity was determined, in cell homogenates, using the NOSdetect assay kit (Alexis 
Biochemicals). Briefly, cells were lysed in buffer containing 25 mM Tris, pH 7.4, 1 mM 
EDTA and 1 mM EGTA and centrifuged for 30 min at 4000 g. 10 l supernatant and 40 L 
reaction buffer (50 mM Tris, 6 M tetrahydrobiopeterin, 2 flavin adenine 
mononucleotide, 2 flavin adenine dinucleotide, 10 mM NADPH, 6 mM CaCl2) containing 
100.000 dpm [
3
H]L-arginine were combined. Following 30 min incubation at room 
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temperature, the enzymatic reaction was stopped by the addition of stop buffer (50 mM 
HEPES, 5 mM EDTA, pH 5.5). Newly formed [
3
H]L-citrulline, neutral at pH 5.5, was then 
separated from the incubation mixture by cation exchange resin (Dowex AG 50 W-X8) and 
quantified using a liquid scintillation counter. The contribution of iNOS to overall NOS 
activity was assessed in similar experiments by replacing the calcium in reaction buffer with 
EGTA (5 mM). Data were normalised by the amount of protein and reaction time. Results 
were expressed as pmol L-citrulline/mg protein/min. 
    In parallel experiments, the cellular homogenates were incubated with N

-hydroxy-nor-L-
arginine (NOHA; 100 M) for 30 min to inactivate arginase activity before measuring the 
NOS activities.   
2.8. Nitrite Detection 
    Nitrite levels were measured by Griess reaction as an index of NO generation following 
conversion of nitrate to nitrite by nitrate dehydrogenase [19].
 
An aliquot of the cellular 
homogenate was mixed with an equal volume of Griess reagent (sulfanilamide 1% w/v, 
naphthylethylenediamine dihydrochloride 0.1% w/v and orthophosphoric acid 2.5% v/v) and 
incubated at room temperature for 10 min prior to measurement of absorbances at 540 nm. 
The amount of nitrite formed was compared to those of known concentrations of sodium 
nitrite and normalised to the protein content of the respective flask. 
2.9. GPx assay 
    The GPx activity was measured using a specific assay kit (Merck Biosciences) based on the 
reduction of oxidised glutathione, produced by GPx-mediated reduction of hydroperoxide, by 
glutathione reductase and NADPH during which the oxidation of NADPH to NADP
+
 was 
accompanied by a decrease in absorbance at 340 nm. Briefly, 100 µl of assay buffer and 50 µl 
of co-substrate mixture were added to 20 µl of untreated and treated CASMC homogenate, in 
triplicate, in a 96-well ELISA plate. Reactions were initiated by the addition of 20 µl cumene 
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hydroperoxide and the sample absorbances were read every 60 sec for 5 min at 340 nm. The 
reaction rate per min was determined for the blank reaction and then subtracted from the 
reaction rates for the analysed samples. GPx activity was then calculated using the extinction 
coefficient for NADPH at 340 nm (0.00373 µM
-1
). One unit of GPx was defined as the 
activity that converts 1 mM of reduced glutathione per litre per min at 25
o
C. 
2.10. SOD Assay 
    The SOD assay kit (Merck Biosciences) utilising a tetrazolium salt for detection of O2
.-
 
generated by xanthine oxidase and hypoxanthine was used. Untreated and treated CASMC 
homogenates were diluted 1:20 with radical detector and assayed in triplicate in a 96-well 
ELISA plate. Reactions were initiated by the addition of 20 µl diluted xanthine oxidase and 
the plate was incubated on a shaker for 20 min at room temperature. Sample absorbance 
values were read at 450 nm and total SOD activity was determined using the equation 
obtained from the linear regression of the SOD standard curve. One unit of SOD was defined 
as the amount of enzyme needed to exhibit 50% dismutation of the O2
.-
 (kit range 0.025-0.25 
units/ml). In similar experiments, MnSOD activity was detected following inhibition of 
CuZn-SOD activity via incubations with 3 mM potassium cyanide (BDH Chemicals Ltd) at 
room temperature for 45 minutes. CuZn-SOD activity was subsequently calculated by the 
subtraction of MnSOD activity from total SOD activity. 
2.11. Evaluation of cell viability 
    To detect cytotoxicity of ROS generating enzyme inhibitors, CASMC were incubated with 
the aforementioned compounds for 75 min. A small aliquot was then incubated with 0.1% 
trypan blue for 4 min and viewed under a light microscope. By counting 100 cells, the 
percentage of viable cells was calculated. 
2.12. Statistical Analysis 
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    To test for directed migration (chemotaxis) the Rayleigh test for unimodal clustering of 
directions was applied to the data and p<0.01 was chosen as the criterion for rejecting the null 
hypothesis of random directionality. Where there was significant unimodal clustering the 
mean direction and its 95% confidence interval were calculated and Tukey’s post hoc analysis 
was conducted. Results for proliferation and enzyme activity assays are presented as 
meanSEM. Statistical analyses were performed by two-way analysis of variance (ANOVA) 
followed by Bonferroni-Dunn’s post hoc analysis and p<0.05 was considered significant. 
3. Results 
3.1. Effects of Ang II and PDGF-BB on CASMC migration 
    Ang II (5-50 nM) evoked significant increases in CASMC chemotaxis. To examine the 
relevance of O2
.-
 to Ang II-mediated migration, cells were treated with a cell-permeable SOD 
mimetic (MnTBAP; 50 M) which significantly attenuated chemotaxis. The prevention of 
Ang II-induced chemotaxis with losartan (0.01-1 M) confirmed the involvement of AT1R in 
Ang II-induced VSMC migration. Mevastatin (10 nM) also inhibited Ang II-mediated 
migration (Fig. 1A). 
    PDGF-BB (5-50 ng/ml) also significantly enhanced CASMC chemotaxis. However, unlike 
Ang II, the PDGF-evoked responses were not affected by MnTBAP and losartan but 
markedly inhibited by mevastatin (Fig. 1B).  
    The cells used in chemotaxis experiments were serum starved for 18 h to exclude the 
migratory effects of serum in order to detect the specific and directed migration produced by a 
given atherogen. As the cells in the absence of stimuli such as serum or atherogens generated 
aberrant undirected migratory responses, they could not be used as positive controls. 
However, the impact of a given treatment on atherogen-mediated chemotaxis was assessed 
using the cells exposed to Ang II or PDGF-BB alone as controls.  
3.2. Effects of Ang II and PDGF-BB on CASMC proliferation 
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    Ang II (5-50 nM) produced significant increases in cell numbers in a dose-dependent 
manner as assessed by cell counting (0.88 ± 0.07 x 10
6
 vs. 1.21 ± 0.15 x 10
6 
and 1.49
 
± 0.13 x 
10
6
 at 5 and 50 nM of Ang II, respectively, n=5, p<0.05) and determination of total protein 
levels (447 ± 16 g vs. 499 ± 21 g and 630 ± 31 g, n=5, p<0.05). The relative changes in 
cell number and protein levels were reflective of the changes in [
3
H]thymidine incorporation 
rates (Fig. 2A). 
    Similar increases in cell numbers (0.88 ± 0.07 x 10
6
 vs. 1.24 ± 0.09 x 10
6 
and 1.43
 
± 0.11 x 
10
6
 at 5 and 50 ng/ml of PDGF-BB, respectively n=5, p<0.05), total protein levels (447 ± 16 
g vs. 510 ± 19 g and 546 ± 18 g, n=5, p<0.05) and [3H]thymidine incorporation rates  
were also obtained with PDGF-BB (Fig. 2B). 
    Treatment of CASMC with MnTBAP (50 μM) reduced cell numbers by approximately 
30% in both Ang II- (1.49
 
± 0.13 x 10
6
 vs. 1.03 ± 0.05 x 10
6
, n=5, p<0.05) and PDGF-BB-
treated (1.43
 
± 0.11 x 10
6
 vs. 0.90 ± 0.06 x 10
6
, n=5, p<0.05) cells. Similar decreases were 
also obtained in [
3
H]thymidine incorporation rates (Fig. 2A-B). Treatment of cells with a 
phagocytic inhibitor of NADPH oxidase i.e. apocynin (100 M) also produced substantial 
decreases in cell growth (Fig. 2A-B). However, the specific inhibitors of xanthine oxidase 
(allopurinol, 10-100 M), cyclooxygenase (indomethacin, 5-50M) and mitochondrial 
complex I inhibitor (rotenone, 5-50 M) did not alter cellular growth rate (data not shown). 
    Similar to apocynin, mevastatin (10 nM) and pravastatin (100 nM) also suppressed cellular 
growth rates in both high dose Ang II- and PDGF-treated cells (Fig. 2A-B).  
3.3. Effects of Ang II and PDGF-BB on enzyme activities 
    Overnight incubation of CASMC with the higher dose of Ang II (50 nM) and both 
concentrations of PDGF-BB (5 and 50 ng/ml) dramatically decreased NOS activity. 
Incubation of cells with mevastatin but not losartan or apocynin alone led to marked increases 
in NOS activity. Mevastatin (10 nM), losartan (1 M) and apocynin (500 M) selectively 
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reversed higher dose Ang II-mediated decreases in NOS activity (Fig. 3A-B). Neither Ang II 
(50 nM; 980 ± 120 vs 1100 ± 100 pmol L-citrulline/mg protein/min, n=3, p<0.05) nor PDGF-
BB (50 ng/ml; 980 ± 120 vs 1210 ± 240 pmol L-citrulline/mg protein/min, n=3, p<0.05) 
significantly altered iNOS activities while the inhibition of arginase activity by NOHA (100 
M) resulted in approximately 6% increase in both atherogen-induced NOS activities.   
    Ang II and PDGF-BB increased NADPH oxidase activity in a dose-dependent fashion 
which was significantly diminished by mevastatin, losartan and apocynin (Fig. 4A-B). The 
level of changes observed in NADPH oxidase activities measured using the total cellular 
homogenates were shown to be representative of those obtained with membrane fractions 
(Table 1). To assess the potential toxic effects of ROS-generating enzyme inhibitors that were 
used in NADPH oxidase assays to eradicate the contributions of enzymes, other than NADPH 
oxidase, to overall O2
.-
 formation, CASMC viability rates were measured which revealed no 
significant difference amongst treatment groups (Table 2).  
    The levels of mitochondrial (MnSOD) and cytosolic SOD (CuZn-SOD) activities were also 
elevated with both atherogens where treatments with mevastatin, losartan and apocynin alone 
abolished both SOD activities and significantly decreased them when used in combination 
with either atherogen (Table 3).  
    Atherogenic agents differentially regulated GPx activity that was dose-dependently 
decreased by Ang II and unaffected by PDGF-BB. It was shown that, when used alone, 
mevastatin but not losartan or apocynin significantly decreased basal GPx activity. Although 
these agents significantly decreased GPx activity in the presence of PDGF-BB, only 
mevastatin was shown to be suppressive to Ang II (Fig. 5A-B). 
3.4. Effects of Ang II and PDGF-BB on O2
.-
 and nitrite levels 
    The differences observed in CASMC NADPH oxidase and NOS activity following 
overnight exposure to Ang II (5-50 nM) or PDGF-BB (5-50 ng/ml) were mimicked by the 
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differences observed in the levels of their end products; O2
.-
 and nitrite, an indirect marker 
used for estimation of NO production, respectively (Table 4). 
3.5. Effects of inhibition of signal transduction pathways on enzyme activities 
    Suppression of tyrosine kinase (TLCK; 50 μM), MAPK (PD98059; 10 μM) or protein 
kinase C (Bis-I; 5 μM) using the indicated specific inhibitors led to atherogen- and enzyme-
specific changes. Individual inhibition of tyrosine kinase and MAPK diminished both PDGF-
BB- and Ang II-mediated GPx activity. However, co-incubation of these inhibitors with Ang 
II enhanced GPx activities compared to control cells and high dose Ang II-treated cells. 
Significant increase in GPx activity was also observed in PDGF-BB and TLCK co-incubated 
versus control cells (Fig. 6A-B). The inhibition of each pathway reduced NADPH oxidase 
and CuZn-SOD enzyme activities compared to higher dose PDGF and Ang II-treated cells by 
almost 50% while concomitantly increasing  NOS activity in these cells (Tables 5 and 6). 
4. Discussion 
    The major conclusions to be drawn from this study are that Ang II and PDGF-BB distinctly 
regulate CASMC proliferation, migration and oxidative status through involvement of 
multiple enzyme systems and signal transduction pathways. These findings provide crucial 
evidence on the mechanisms whereby these agents may contribute to vasculopathologies in 
addition to their well-established vasoconstrictor and mitogenic effects. 
    The migration of SMC to the intimal space constitutes one of the key events in the 
atherosclerotic lesion formation and is mediated by various growth factors and cytokines. To 
substantiate these, the present study has shown that both PDGF-BB (≥5 ng/ml) and Ang II (≥5 
nM) produce significant CASMC chemotaxis. In SMC, Ang II through AT1R-mediated 
induction of NADPH oxidase, increases O2
.- 
production which in turn scavenges NO and 
stimulates migration [9-11,20,21]. Indeed, losartan (AT1R blocker) and MnTBAP have 
selectively inhibited Ang II- but not PDGF-BB-dependent chemotaxis. These findings imply 
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that neutralisation of O2
.-
 is a prerequisite for efficacious inhibition of Ang II-evoked SMC 
migration and that reduced oxidative stress has no benefit for PDGF-BB-induced migration 
supporting previous studies with aortic VSMC and those showing a prerequisite for PDGF-β 
receptor binding for chemotaxis [22,23].  
    Contrary to losartan, mevastatin abolished CASMC migration regardless of the atherogenic 
agent used. Our recent study has attributed this effect to the ability of statins to prevent 
prenylation of small monomeric GTPases as evidenced by recovery of migration following 
microinjection of isoprenoid intermediate farnesylpyrophosphate (FPP) and further 
attenuation of migration by Ras/MAPK pathway inhibition via a farnesyltransferase inhibitor 
[24]. The critical roles of Ras and other small GTP-binding proteins including p21 Rac in the 
assembly of the NADPH oxidase enzyme system, cell proliferation, NOS activity and thus 
NO generation may help explain the beneficial effects of statins on preventing and/or 
regressing atherosclerotic plaque development [25,26]. 
    In addition to cell migration, proliferation which contributes to in-stent restenosis is also 
considered a key feature of atherosclerosis [27]. Hence, the present study investigated the 
correlation between atherogenic agents and CASMC proliferation and revealed that both 
atherogens increased O2
.-
 production and CASMC proliferation in a dose-dependent manner 
which were suppressed by MnTBAP, apocynin and mevastatin. Taken with the migration 
studies these data imply that while ROS modulate both Ang II-mediated CASMC 
proliferation and migration, they are solely associated with PDGF-induced proliferative 
processes. It is of note that differential regulation of VSMC proliferation and chemotaxis is 
not unique to the agents used in this study, as similar effects have been generated with 
VAS2870, a novel NADPH oxidase inhibitor, in rat thoracic aorta SMC [29]. In this context, 
a previous study has attributed normal coronary endothelial cell growth to NADPH oxidase-
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derived O2
.-
 bioavailability, a finding supported in this study by inability of other ROS-
generating enzymes to alter CASMC proliferation rates [26]. 
    NO inhibits proliferation of several cells and thus prevents atherosclerotic disease 
progression [28]. Since, similar to previous studies, no significant differences in iNOS 
activity were detected in CASMC incubated with/out Ang II and PDGF-BB, the enhanced cell 
growth was investigated in relation to potential differences in eNOS activity and nitrite levels, 
a surrogate marker of NO [30,31]. These studies revealed that both Ang II and PDGF-BB 
produced significant dose-dependent reductions in both parameters where treatments of cells 
with mevastatin but not apocynin or losartan alone enhanced NOS activity. Furthermore, 
while these agents normalised Ang II-mediated decreases in NOS activity, they failed to 
reverse those brought about by PDGF-BB which sheds some light on their inability to 
suppress PDGF-BB-evoked chemotaxis. 
    Given that NADPH oxidase-derived O2
.-
 determines the availability of NO, the effects of 
atherogenic agents on this enzyme activity were investigated which demonstrated dose-
dependent elevations with both agents. Interestingly, incubation of CASMC with mevastatin 
alone also enhanced NADPH oxidase activity. Although the mechanism behind this increase 
is unknown, it is possible that mevastatin-induced dramatic increases in NO bioavailability 
may diminish local O2
.-
 levels thereby stimulating NADPH oxidase activity through a 
negative feed back mechanism. Indeed, the combinations of either atherogen with mevastatin, 
apocynin or losartan have led to reduced enzymatic activities compared to sole Ang II or 
PDGF-BB treatments. In this context, our previous studies have shown using endothelial cells 
that Ang II increases eNOS activity via concomitant involvement of its type 1 and type 2 
receptor subtypes and also enhances cell proliferation and NADPH oxidase which are 
attenuated by MnTBAP, apocynin or antisense p22-phox (a pivotal subunit of NADPH 
oxidase) cDNA treatments [32-34].  
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       Antioxidant enzymes including SOD and GPx also play critical roles in determining the 
overall intracellular oxidative status. Under physiological conditions, SODs convert O2
.-
 to 
H2O2 that in turn is metabolised to H2O by catalase and GPx, a pathway that may be perturbed 
in pathological conditions [12]. This study has shown that both Ang II and PDGF-BB have 
increased both CuZn-SOD (the main isotype which accounts for ~80% of total SOD activity) 
and MnSOD activities, a strong indicator of elevated intracellular oxidative stress, which were 
significantly attenuated by mevastatin, apocynin or losartan. Considering the suppressive 
effects of these agents on NADPH oxidase and hence O2
.-
 production, these results were 
somewhat expected. However, the data pertaining to GPx activity were rather unexpected and 
displayed an atherogen-dependent regulation in that while Ang II elicited a dose-dependent 
decrease in its activity, PDGF-BB did not affect its basal activity. Besides, while mevastatin, 
losartan and apocynin significantly decreased GPx activity when co-incubated with PDGF-
BB, both losartan and apocynin failed to alter Ang II-induced GPx activity. 
    Variety of signal transduction pathways including tyrosine kinases, protein kinase C and 
MAPK activated by Ang II and PDGF are implicated in VSMC differentiation, migration and 
proliferation [35,36]. In this study, selective inhibition of these signal transduction pathways 
to examine the putative links between their impaired regulation and promotion of pathological 
cascades have shown an atherogen- and/or enzyme-specific changes in enzyme activities. For 
example, suppressions of tyrosine kinase and MAPK enhanced Ang II- but not PDGF-
mediated GPx activity. In contrast, selective inhibition of each pathway displayed similar 
effects on NADPH oxidase, CuZn-SOD and NOS activities. The similarities in these 
responses can in part be explained by the well-documented presence of a cross-talk between 
G-protein coupled AT1R and the PDGF receptor tyrosine kinase in vascular SMCs and thus 
the ability of Ang II to elicit responses unique to growth factor stimulation [15,16,37]. 
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    In conclusion, statins, free radical scavengers and ARB may suppress the early events in 
atherogenesis by markedly inhibiting overall oxidative stress status, SMC migration and/or 
proliferation. Intracellular antioxidants and ARB suppress Ang II-mediated but not PDGF-
BB-induced chemotaxis despite equally blocking cellular proliferation to both agents. 
Considering the involvement of different signal transduction pathways in the regulation of 
pro- and anti-oxidant enzyme activities, it is important to reiterate that Ang II and PDGF-BB 
may induce vascular complications by stimulating CASMC migration and proliferation 
through agent-specific regulation of oxidative status and utilisation of different signal 
transduction pathways. 
Acknowledgements 
    This study was supported by grants to Dr Bayraktutan from the Stroke Association, UK and 
the Institute of Neuroscience, University of Nottingham. The authors wish to thank Dr 
Malcolm Campbell, Queen’s University Belfast for his help and comments on migration 
assays.  
References 
[1] Ross R. Atherosclerosis – an inflammatory disease. New Engl J Med 1999;340:115-
26.  
[2] Grandaliano G, Biswas P, Choudhury GG, Abboud HE. Simvastatin inhibits PDGF-
induced DNA synthesis in human glomerular mesangial cells. Kidney Int 
1993;44:503-8. 
[3] Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol 
lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin 
Survival Study (4S). Lancet 1994;344:1383-9. 
[4] Shepherd J, Cobbe SM, Ford I, Isles CG, Lorimer AR, MacFalane PW, et al. 
Prevention of coronary heart disease with pravastatin in men with 
   
 
 18 
hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J 
Med 1995;333:1301-7. 
[5] Campbell M, Allen WA, Sawyer C, Vanhaesebroeck B, Trimble ER. Glucose-
potentiated chemotaxis in human vascular smooth muscle is dependent on cross-talk 
between the PI3K and MAPK signaling pathways. Circ Res 2004;95:380-8. 
[6] Holtz J, Goetz RM. Vascular renin-angiotensin-system, endothelial function and 
atherosclerosis? Basic Res Cardiol 1994;89:71-86. 
[7] The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an 
angiotensin-converting-enzyme inhibitor, ramipril on cardiovascular events in high 
risk patients. N Engl J Med 2000;342:145-53. 
[8] Kohno M, Ohmori K, Nozaki S, Mizushige K, Yasnuari K, Kano H, et al. Effects of 
valsartan on angiotensin II-induced migration of human coronary artery smooth 
muscle cells. Hypertension Res 2000;23:677-81. 
[9] Griendling KK, Sorescu D, Ushio-Fukai M. NADPH oxidase: role in cardiovascular 
biology and disease. Circ Res 2000;86:494-501. 
[10] Bey EA, Cathcart, MK. In vitro knockout of human p47-phox blocks superoxide 
anion production and LDL oxidation by human monocytes. J Lipid Res 2000;41:489-
95. 
[11] Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate 
endothelium-derived relaxing factor. Am J Physiol 1986;250:H822-77. 
[12] Yu BP. Cellular defenses against damage from reactive oxygen species. Physiol Rev 
1994;74:139-62. 
[13] Molloy CJ, Taylor DS, Weber H. Angiotensin II stimulation of rapid protein tyrosine 
phosphorylation and protein kinase activation in rat aortic smooth muscle cells. J Biol 
Chem 1993;268:7338-45. 
   
 
 19 
[14] Huckle WR, Dy RC, Earp HS. Calcium-dependent increase in tyrosine kinase activity 
stimulated by angiotensin II. Proc Natl Acad Sci USA 1992; 89:8837-41. 
[15] Nadal JA, Scicli GM, Carbini LA, Scicli AG. Angiotensin II stimulates migration of 
retinal microvascular pericytes: involvement of TGF-  and PDGF-BB.  
Am J Physiol 2002;282:H739-48. 
[16] Eskilsend-Helmond YE, Mulvany MJ. Pressure-induced activation of extracellular 
signal-regulated kinase 1/2 in small arteries. Hypertension 2003;41:891-7. 
[17] Campbell M, Trimble ER.  Modification of PI3K- and MAPK-dependent chemotaxis 
in aortic vascular smooth muscle cells by protein kinase CII. Circ Res 2005;96:197-
206. 
[18] Zicha D, Dunn G, Jones G. Analyzing chemotaxis using the Dunn direct-viewing 
chamber. Methods Mol Biol 1997;75:449-57. 
[19] Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. 
Analysis of nitrate, nitrite and [
15
N] nitrate in biological fluids. Anal Biochem 
1982;126:131-8. 
[20] Nickenig G, Sachinidis A, Michaelsen F, Bohm M, Seewald S, Vetter H. 
Upregulation of vascular angiotensin II receptor gene expression by LDL in vascular 
smooth muscle cells. Circulation 1997;95:473-8. 
[21] Lo IC, Shih JM, Jiang MJ. Reactive oxygen species and ERK 1/2 mediate monocyte 
chemotactic protein-1-stimulated smooth muscle cell migration. J Biomed Sci 
2005;12:377-88. 
[22] Kappert K, Sparwel J, Sandin A, Seiler A, Siebolts U, Leppanen O, et al. Antioxidants 
relieve phosphatase inhibition and reduce PDGF signaling in cultured VSMCs and in 
restenosis. Arterioscler Thromb Vasc Biol 2006;26:2644-51. 
   
 
 20 
[23] Campbell M, Allen WE, Silversides JA, Trimble ER. Glucose-induced 
phosphatidylinositol 3-kinase and mitogen-activated protein kinase-dependent 
upregulation of the platelet-derived growth factor-beta receptor potentiates vascular 
smooth muscle cell chemotaxis. Diabetes 2003;52:519-26. 
[24] Mahadevan VS, Campbell M, McKeown PP, Bayraktutan U. Internal mammary 
artery smooth muscle cells resist migration and possess high antioxidant capacity. 
Cardiovasc Res 2006;72:60-8. 
[25] Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric 
oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through 
attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 
2000;20:61-9. 
[26] Hall A. Rho GTPases and the actin cytoskeleton. Science 1998;279:509-14. 
[27] Dzau VJ, Braun-Dullaeus RC, Sedding DG. Vascular proliferation and 
atherosclerosis: new perspectives and therapeutic strategies. Nat Med 2002;8:1249-
56. 
[28] Bayraktutan U. Nitric Oxide Synthase and NADPH Oxidase Enzymes Modulate 
Coronary Endothelial Cell Growth. J Mol Cell Cardiol 2004;36:277-86. 
[29] Freyhaus H, Huntgeburth M, Wingler K, Schnitker J, Baumer AT, Vantler M, et al. 
Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell 
chemotaxis but not proliferation. Cardiovasc Res 2006;71:331-41. 
[30] Jiang B, Xu S, Hiu X, Pimentel D, Cohen RA. Angiotensin II differentially regulates 
interleukin-1--iNOS and VCAM-1 expression. J Biol Chem 2004;279:20363-8. 
[31] Nakata S, Tsutsui M, Shimokawa H, Tamura M, Tasaki H, Morishita T, et al. 
Vascular neuronal NO synthase is selectively upregulated by platelet-derived growth 
factor. Arterioscler Thromb Vasc Biol 2005;25:2502-8. 
   
 
 21 
[32] Bayraktutan U. Coronary microvascular endothelial cell growth regulates expression 
of the gene encoding p22-phox. Free Rad Biol Med 2005;39:1342-52. 
[33] Bayraktutan U, Ulker S. Effects of angiotensin II on nitric oxide generation in 
proliferating and quiescent rat coronary microvascular endothelial cells. Hypertens 
Res 2003;26:749-57. 
[34] Bayraktutan U. Effects of ang II on nitric oxide generation in growing and resting rat 
aortic endothelial cells. J Hypertens 2003;21:2093-101. 
[35] Parmentier HJ, Zhang C, Estes A, Schaefer S, Malik KU. Essential role of PKC- in 
normal and angiotensin II-accelerated neointimal growth after vascular injury. Am J 
Physiol Heart Circ Physiol 2006;291:H1602-13. 
[36] Pelech SL, Shanghera JS. MAP kinases: charting the regulatory pathways. Science 
1992;257:1355-6. 
[37] Linseman DA, Benjamin CW, Jones DA. Convergence of angiotensin II and platelet-
derived growth factor receptor signalling cascades in vascular smooth muscle cells. J 
Biol Chem 1995;270:12563-8. 
 
 
 
 
 
 
 
 
 
 
 
   
 
 22 
Legends 
Fig. 1. Effects of angiotensin II (A) and PDGF-BB (B) on coronary artery smooth muscle cell 
migration in the absence or presence of a cell-permeable superoxide dismutase mimetic 
(MnTBAP), angiotensin II type 1 receptor blocker (losartan) and a statin (mevastatin). n≥30 
cells from 3 independent experiments were used. *p<0.01 (Rayleigh test: chemotaxis 
detected), 
†
p<0.05 (t-Test: % migrating cells versus the higher dose of Ang II or PDGF-BB). 
Fig. 2. Effects of angiotensin II (A) and PDGF-BB (B) on [
3
H]thymidine incorporation in 
coronary artery smooth muscle cells in the absence or presence of a cell-permeable 
superoxide dismutase mimetic (MnTBAP), an NADPH oxidase inhibitor (apocynin) and two 
statins (mevastatin and pravastatin). Data are expressed as mean ± SEM from 4 different 
experiments. *p<0.05 compared to control groups. 
†
p<0.05 compared to the higher dose of 
Ang II or PDGF-BB groups. 
Fig. 3. Effects of angiotensin II (A) and PDGF-BB (B) on nitric oxide synthase (NOS) 
activity in the absence or presence of a statin (mevastatin), an angiotensin II type 1 receptor 
blocker (losartan) and an NADPH oxidase inhibitor (apocynin). Data are expressed as mean ± 
SEM from 3 different experiments. *p<0.05 compared to control groups. 
†
p<0.05 compared to 
the higher dose of Ang II or PDGF-BB groups. 
Fig. 4. Effects of angiotensin II (A) and PDGF-BB (B) on NADPH oxidase activity in the 
absence or presence of a statin (mevastatin), an angiotensin II type 1 receptor blocker 
(losartan) and an NADPH oxidase inhibitor (apocynin). Data are expressed as mean ± SEM 
from 3 different experiments. *p<0.05 compared to control groups. 
†
p<0.05 compared to the 
higher dose of Ang II or PDGF-BB groups. 
Fig. 5. Effects of angiotensin II (A) and PDGF-BB (B) on glutathione peroxidase (GPx) 
activity in the absence or presence of a statin (mevastatin), an angiotensin II type 1 receptor 
blocker (losartan) and an NADPH oxidase inhibitor (apocynin). Data are expressed as mean ± 
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SEM from 3 different experiments. *p<0.05 compared to control groups. 
†
p<0.05 compared to 
the higher dose of Ang II or PDGF-BB groups. 
Fig. 6. Effects of suppression of tyrosine kinase (TLCK), mitogen activated protein kinase 
(PD98059) or protein kinase C (Bis-I) on angiotensin II (A) and PDGF-BB-mediated (B) 
changes in glutathione peroxidise activities. Data are expressed as mean ± SEM from 3 
different experiments. *p<0.05 compared to control groups. 
†
p<0.05 compared to the higher 
dose of Ang II or PDGF-BB groups. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure 4 
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Figure 5 
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Figure 6 
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Table 1. The effects of Ang II and PDGF-BB on NADPH oxidase activities of whole cellular and membrane fractions and the effects of mevastatin, pravastatin, losartan and valsartan. 
 
 
The levels of NADPH oxidase activities were measured in coronary artery vascular smooth muscle cells (CASMC) cultured with Ang II or PDGF-BB for 24 hours in the absence or 
presence of mevastatin, pravastatin losartan and valsartan. Results expressed as mean±SEM from four separate experiments. RLU; relative light unit. *p<0.05 difference compared to 
Ang II or PDGF-BB treatment groups. 
 
 
 
 
 
 
 
 
 
 
 
Treatment Group 
Cellular 
 (RLU/g.min) 
Membrane  
(RLU/g.min) 
Treatment Group 
Cellular 
 (RLU/g.min) 
Membrane 
(RLU/g.min) 
Ang II 50 nM 210 ± 22 92 ± 13 PDGF-BB 50 ng/mL 145 ± 18 64 ± 8 
Mevastatin (10 nM) 139 ± 16* 55 ± 8* Mevastatin (10 nM) 84 ± 15* 36 ± 4* 
Pravastatin (100 nM) 127 ± 14* 52 ± 8* Pravastatin (100 nM) 86 ± 11* 39 ± 6* 
Losartan (1 M) 89 ± 14* 33 ± 5* Losartan (1 M) 76 ± 10* 29 ± 5* 
Valsartan (1 M) 93 ± 11* 36 ± 4* Valsartan (1 M) 79 ± 11* 32 ± 4* 
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Table 2. The effects of Ang II, PDGF-BB and reactive oxygen species generating enzyme inhibitors on coronary artery smooth muscle cell 
viability. 
Treatment Group Viable Cells (%) 
Control 92 ± 4 
Ang II (50 nM) 94 ± 5 
PDGF-BB (50 ng/ml) 93 ± 5 
Rotenone (50 M) 91 ± 3 
L-NAME (100 M) 90 ± 3 
Allopurinol (100 M) 93 ± 5 
Indomethacin (50 M) 94 ± 4 
NOHA (100 M) 92 ± 3 
 
 
Percentage viable cells were determined by trypan blue exclusion experiments through counting 100 cells. Data are expressed as mean ± SEM 
from 4 different experiments. 
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Table 3. The effects of Ang II and PDGF-BB on superoxide dismutase enzyme capacities and the effects of a statin (mevastatin), an ARB (losartan) and an NAD(P)H oxidase inhibitor 
(apocynin). 
 
 
The levels of superoxide dismutase enzyme activities were measured in coronary artery vascular smooth muscle cells (CASMC) cultured with Ang II or PDGF-BB for 24 hours in the 
absence or presence of mevastatin, losartan and apocynin. Results expressed as mean±SEM from three separate experiments. ARB: angiotensin II type I receptor blocker; SOD: 
superoxide dismutase. *p<0.05 difference compared to basal untreated group. 
†
p<0.05 difference compared to higher dose Ang II or PDGF-BB treatment groups. 
 
Treatment Group 
CuZn-SOD (mU/mg 
protein) 
Mn-SOD (mU/mg 
protein) 
Treatment Group 
CuZn-SOD (mU/mg 
protein) 
Mn-SOD (mU/mg 
protein) 
Basal 38 ± 2
†
 5 ± 1
†
 Basal 38 ± 1
†
 5 ± 1
†
 
Ang II 5 nM 110 ± 10
*†
 44 ± 3
*†
 PDGF-BB 5 ng/mL 81 ± 4
*†
 36 ± 1
*†
 
Ang II 50 nM 129 ± 8
*
 60 ± 2
*
 PDGF-BB 50 ng/mL 140 ± 16
*
 66 ± 3
*
 
Mevastatin 10
-7 
mM 8 ± 1
*†
 2 ± 0.5
*†
 Mevastatin 10
-7 
mM 8 ± 1
*†
 2 ± 0.5
*†
 
Losartan 10
-6 
mM 12 ± 1.1
*†
 3 ± 0.5
*†
 Losartan 10
-6 
mM 12 ± 1.1
*†
 3 ± 0.5
*†
 
Apocynin 500 μM 6 ± 1*† 1 ± 0.5*† Apocynin 500 μM 6 ± 1*† 1 ± 0.5*† 
Ang II 50 nM + Mevastatin 83 ± 6
*†
 7 ± 3
†
 PDGF-BB 50 ng/mL + Mevastatin 99 ± 10
*†
 15 ± 3
*†
 
Ang II 50 nM + Losartan 61 ± 11
*†
 21 ± 4
*†
 PDGF-BB 50 ng/mL + Losartan 81 ± 7
*†
 10 ± 4
*†
 
Ang II 50 nM + Apocynin 31 ± 3
*†
 22 ± 5
*†
 PDGF-BB 50 ng/mL + Apocynin 62 ± 3
*†
 5 ± 2
†
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Table 4. The effects of Ang II and PDGF-BB on nitrite and O2
.-
 production 
Treatment Group Nitrite 
(nmol/mg protein) 
Superoxide anion 
(pmole O2
.-
/mg protein) 
Basal 29 ± 2 0.015 ± 0.002 
Ang II 5 nmol/L 33 ± 3
† 
0.036 ± 0.003*
†
 
Ang II 50 nmol/L 21 ± 2
*
 0.057 ± 0.004* 
PDGF-BB 5 ng/ml 20 ± 3
*
 0.024 ± 0.002*
†
 
PDGF-BB 50 ng/ml 18 ± 2
*
 0.033 ± 0.002* 
 
The levels of nitrite and O2
.-
 were measured in coronary artery smooth muscle cells (CASMC) cultured with indicated concentrations of Ang II and PDGF-BB for 24 hours. Results 
are expressed as mean±SEM from five separate experiments. *p<0.05 difference compared to basal untreated group. 
†
p<0.05 difference in each treatment group. 
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Table 5. The effects of Ang II on NAD(P)H oxidase, CuZn-SOD and NOS activities in the absence or presence of a serine protease inhibitor tosyl-L-lysine chloromethyl 
ketone (TLCK), a MAPK inhibitor (PD98059) and a protein kinase C inhibitor (Bis-I).  
 
 
 
 
 
 
 
 
 
 
 
 
The enzyme activities were measured in coronary artery smooth muscle cells (CASMC) cultured with Ang II for 24 hours in the absence or presence of indicated signal 
transduction pathway inhibitors. Results expressed as mean ± SEM from three separate experiments. NOS: nitric oxide synthase; SOD: superoxide dismutase. *p<0.05 
difference compared to basal untreated group. 
†
p<0.05 difference compared to Ang II 50nM treatment group. 
 
 
 
 
Treatment Group 
NAD(P)H Oxidase 
 (pmol O2
.-
/mg protein) 
CuZn-SOD            
(mU/mg protein) 
NOS                           
 (pmol L-citrulline/mg protein/min) 
Basal 0.036 ± 0.005 38 ± 2 10290 ± 1296.1 
Ang II 50nM 0.149 ± 0.005
*
 129 ± 8
*
 6802.8 ± 138
*
 
TLCK 50μM 0.038 ± 0.007† 51 ± 8*† 12952.8 ± 924.4*† 
PD98059 10μM 0.034 ± 0.005† 37 ± 3† 13178.9 ± 1248.3*† 
Bis-I 5μM 0.042 ± 0.002† 47 ± 4† 15720.6 ± 277.9*† 
Ang II 50nM + TLCK 50μM 0.064 ± 0.008*† 102 ± 7* 12146.7 ± 704.4*† 
Ang II 50nM + PD98059 10μM 0.050 ± 0.004*† 85 ± 11*† 10548.9 ± 2010.6† 
Ang II 50nM + Bis-I 5μM 0.036 ± 0.002† 119 ± 13* 12234.6 ± 487.6*† 
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Table 6. The effects of PDGF-BB on NAD(P)H oxidase, CuZn-SOD and NOS activities in the absence or presence of a serine protease inhibitor tosyl-L-lysine chloromethyl 
ketone (TLCK), a MAPK inhibitor (PD98059) and a protein kinase C inhibitor (Bis-I).  
 
 
 
 
 
 
 
 
 
 
 
The enzyme activities were measured in coronary artery smooth muscle cells (CASMC) cultured with PDGF-BB for 24 hours in the absence or presence of indicated signal 
transduction pathway inhibitors. Results expressed as mean ± SEM from three separate experiments. NOS: nitric oxide synthase; SOD: superoxide dismutase. *p<0.05 
difference compared to basal untreated group. 
†
p<0.05 difference compared to PDGF-BB 50ng/ml treatment group. 
 
 
 
 
 
 
Treatment Group 
NAD(P)H Oxidase 
(pmol O2
.-
/mg protein) 
CuZn-SOD             
(mU/mg protein) 
NOS                           
 (pmol L-citrulline/mg protein/min) 
Basal 0.036 ± 0.005 38 ± 2 10290 ± 1296.1 
PDGF-BB 50ng/mL 0.079 ± 0.008
*
 140 ± 16
*
 5797.3 ± 948.8
*
 
TLCK 50μM 0.038 ± 0.007† 51 ± 8*† 12952.8 ± 924.4*† 
PD98059 10μM 0.034 ± 0.005† 37 ± 3† 13178.9 ± 1248.3*† 
Bis-I 5μM 0.042 ± 0.002† 47 ± 4† 15720.6 ± 277.9*† 
PDGF-BB  50ng/mL + TLCK 50μM 0.038 ± 0.001† 63 ± 1*† 10664.9 ± 745.3† 
PDGF-BB 50ng/mL + PD98059 10μM 0.034 ± 0.005† 81 ± 8*† 9789.5 ± 361.2† 
PDGF-BB 50ng/mL + Bis-I 5μM 0.042 ± 0.005† 53 ± 9*† 11345.6 ± 1047.1† 
